TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 23350190
Drug: Ribavirin in
Normalized name: ribavirin Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ribavirin in combination with cycloferon
Study: 15811981
Drug: 380 mg
Normalized name: aspirin 380 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 380 mg long-acting naltrexone
Study: 15811981
Drug: 190 mg
Normalized name: papain 190 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 190 mg long-acting naltrexone
Study: 8447208
Drug: Sufentanil (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sufentanil (2 micrograms kg‐1 intravenous bolus) with neurolept analgesia
Study: 8447208
Drug: Sufentanil (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sufentanil (2 micrograms kg‐1 intravenous bolus) with halothane
Study: 8447208
Drug: Sufentanil (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sufentanil (2 micrograms kg‐1 intravenous bolus) with enflurane
Study: 8447208
Drug: Sufentanil (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sufentanil (2 micrograms kg‐1 intravenous bolus) with isoflurane
Study: 3961308
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of social, medical and psychological interventions
Study: 27445550
Drug: IPPB therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: IPPB therapy
Study: 27445550
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of IPPB and PEEP therapy
Study: 27445550
Drug: PEEP therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: PEEP therapy
Study: 27445550
Drug: IPPB and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: IPPB and PEEP therapy
Study: 22510537
Drug: Behavioral physical
Normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Behavioral physical therapy interventions
Study: 19092235
Drug: Metformin (1,500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin (1,500 mg daily) + IPL therapy
Study: 19092235
Drug: IPL therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: IPL therapy alone
Study: 17251674
Drug: Geometric mean
Normalized name: OCTINOXATE 0.0664 g in 1 g / OXYBENZONE 0.0151 g in 1 g TOPICAL LIPSTICK [ESIKA HYDRACOLOR 2 IN 1 SPF 25 (ROSA GEOMETRIC) - PINK]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Geometric mean of log minimum dose (Dmin) in CSA patients
Study: 17251674
Drug: Geometric mean
Normalized name: OCTINOXATE 0.0664 g in 1 g / OXYBENZONE 0.0151 g in 1 g TOPICAL LIPSTICK [ESIKA HYDRACOLOR 2 IN 1 SPF 25 (ROSA GEOMETRIC) - PINK]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Geometric mean of log minimum dose (Dmin) in CP patients
Study: 17251674
Drug: Geometric mean
Normalized name: OCTINOXATE 0.0664 g in 1 g / OXYBENZONE 0.0151 g in 1 g TOPICAL LIPSTICK [ESIKA HYDRACOLOR 2 IN 1 SPF 25 (ROSA GEOMETRIC) - PINK]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Geometric mean of log minimum dose (Dmin) in control subjects
Study: 7968646
Drug: Estradiol (E2)
Normalized name: Estradiol
DrugBank: Estradiol acetate (DB13952)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Estradiol (E2) TTS 0.05 mg/day for 6 months and 0.025 mg/day for the following six months
Study: 7968646
Drug: Estradiol (E2)
Normalized name: Estradiol
DrugBank: Estradiol acetate (DB13952)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Estradiol (E2) TTS 0.10 mg/day for the first 6 months and 0.05 mg/day for the following 6 months
Study: 3112729
Drug: Haemophilus influenzae
Normalized name: HAEMOPHILUS INFLUENZAE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Haemophilus influenzae type b polysaccharide-Neisseria meningitidis outer membrane protein conjugate vaccine (15 micrograms polysaccharide and 51 micrograms protein)
Study: 26319483
Drug: Intravenous dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous dexamethasone (1.0 mg/kg)
Study: 23354394
Drug: Bitter orange
Normalized name: BITTER ORANGE
DrugBank: Citrus aurantium fruit (DB16598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bitter orange extract (approximately 49mg p-synephrine) plus naringin and hesperidin, twice daily for 60 days
Study: 23354394
Drug: Bitter orange
Normalized name: BITTER ORANGE
DrugBank: Citrus aurantium fruit (DB16598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bitter orange extract (approximately 49mg p-synephrine) alone, twice daily for 60 days
Study: 23354394
Drug: Placebo, twice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, twice daily for 60 days
Study: 16831092
Drug: 0.3 mg
Normalized name: biotin 0.3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.3 mg JS2 DNA
Study: 16831092
Drug: 3 mg
Normalized name: boron 3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 mg JS2 DNA
Study: 16831092
Drug: JS2 DNA
Normalized name: TOXOPLASMA GONDII DNA
Approvals — FDA: no, EMA: no, PMDA: no
Description: JS2 DNA (both doses)
Study: 10770766
Drug: Quinine at
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quinine at 10 mg/kg three times a day for 7 days (Q)
Study: 10770766
Drug: Artemisinin at
Normalized name: artemisinin
DrugBank: Artemisinin (DB13132)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Artemisinin at 20 mg/kg followed by quinine for 3 days (AQ3)
Study: 10770766
Drug: Artemisinin at
Normalized name: artemisinin
DrugBank: Artemisinin (DB13132)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Artemisinin at 20 mg/kg followed by quinine for 5 days (AQ5)
Study: 9340504
Drug: Double-bolus alteplase
Normalized name: Alteplase
DrugBank: Alteplase (DB00009)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Double-bolus alteplase (50 mg over 1-3 minutes followed by 50 mg 30 minutes later, or 40 mg for patients <60 kg)
Study: 9340504
Drug: Accelerated infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Accelerated infusion of alteplase (100 mg over 90 minutes)
Study: 9340504
Drug: Accelerated infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Accelerated infusion of alteplase
Study: 3110981
Drug: misoprostol 400
Normalized name: Misoprostol 400 microgram oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: misoprostol 400 micrograms, twice daily for up to 8 weeks
Study: 3110981
Drug: ranitidine 150
Normalized name: ranitidine 150 MG
DrugBank: Ranitidine (DB00863)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ranitidine 150 mg, twice daily for up to 8 weeks
Study: 26963198
Drug: Non-pedicled buccal
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-pedicled buccal fat pad graft (BFPG)
Study: 19213086
Drug: Enoxaparin 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enoxaparin 0.5 mg/kg with closure device
Study: 19213086
Drug: Enoxaparin 0.75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enoxaparin 0.75 mg/kg with closure device
Study: 19213086
Drug: Enoxaparin 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enoxaparin 0.5 mg/kg with smaller sheath size (<7 Fr)
Study: 19213086
Drug: Enoxaparin 0.75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enoxaparin 0.75 mg/kg with smaller sheath size (<7 Fr)
Study: 15111165
Drug: Heparin-coated circuit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin-coated circuit (group H)
Study: 9153333
Drug: Scrotal system
Approvals — FDA: no, EMA: no, PMDA: no
Description: Scrotal system (Testoderm Testosterone Transdermal System) delivering approximately 4 mg testosterone over 24 hours
Study: 9153333
Drug: Nonscrotal system
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonscrotal system (Androderm Testosterone Transdermal System) providing approximately 5 mg testosterone over 24 hours
Study: 24014884
Drug: 5-fluorouracil continuous
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-fluorouracil continuous infusion (800 mg/m2/day, ci, d1-5, q4w)
Study: 24014884
Drug: Methotrexate and
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Methotrexate and 5-fluorouracil therapy (methotrexate, 100 mg/m2, bolus infusion, followed 3 h later by 5-fluorouracil, 600 mg/m2, bolus infusion, with leucovorin rescue, q1w)
Study: 18454257
Drug: Natural honey
Normalized name: Robitussin Cough Drop Herbal With Natural Honey Center
Approvals — FDA: no, EMA: no, PMDA: no
Description: Natural honey (70 g daily for 30 days)
Study: 18454257
Drug: Sucrose (70
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sucrose (70 g daily for 30 days)
Study: 16911289
Drug: Topical methyl
Normalized name: methylal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical methyl aminolaevulinate (MAL) photodynamic therapy (PDT) (160 mg g1)
Study: 16911289
Drug: Topical methyl
Normalized name: methylal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical methyl aminolaevulinate (MAL) photodynamic therapy (PDT)
Study: 12821233
Drug: Intravenous acetylcysteine
Normalized name: Acetylcysteine
DrugBank: Acetylcysteine magnesium (DB14080)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous acetylcysteine (NAC) 150 mg/kg in 500 ml N/saline over 30 min immediately before contrast followed by 50 mg/kg in 500 ml N/saline over 4 h (n = 41)
Study: 12821233
Drug: Intravenous hydration
Normalized name: Chloral Hydrate
DrugBank: Chloral hydrate (DB01563)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous hydration (1 ml/kg/h N/saline for 12 h pre‐ and post‐contrast, n = 39)
Study: 10913474
Drug: Abciximab plus
Normalized name: Abciximab
DrugBank: Abciximab (DB00054)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Abciximab plus heparin (70 U/kg)
Study: 10913474
Drug: Heparin alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin alone (70 U/kg)
Study: 1517792
Drug: Busulfan (BU)
Normalized name: Busulfan
DrugBank: Busulfan (DB01008)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Busulfan (BU) 16 mg/kg and Cyclophosphamide (CY) 120 mg/kg
Study: 1517792
Drug: Busulfan (BU)
Normalized name: Busulfan
DrugBank: Busulfan (DB01008)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Busulfan (BU) 14 mg/kg and Cyclophosphamide (CY) 120 mg/kg
Study: 1517792
Drug: Busulfan (BU)
Normalized name: Busulfan
DrugBank: Busulfan (DB01008)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Busulfan (BU) 14 mg/kg and Cyclophosphamide (CY) 147 mg/kg
Study: 1517792
Drug: Busulfan (BU)
Normalized name: Busulfan
DrugBank: Busulfan (DB01008)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Busulfan (BU) 14 mg/kg and Cyclophosphamide (CY) 174 mg/kg
Study: 6471030
Drug: Influenza Vaccine
Normalized name: Influenza vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Influenza Vaccine A
Study: 6471030
Drug: Influenza Vaccine
Normalized name: Influenza vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Influenza Vaccine B
Study: 26641555
Drug: Interventions for
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Interventions for patients naïve to depression screening, pneumococcal vaccination, inhaled control medications, or smoking cessation.
Study: 20716817
Drug: tgAAC09 vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: tgAAC09 vaccine (3x10^9, 3x10^10, and 3x10^11 DNase resistant particles/ml)
Study: 20716817
Drug: tgAAC09 vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: tgAAC09 vaccine (high dose)
Study: 20716817
Drug: tgAAC09 vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: tgAAC09 vaccine (low and mid-dose)
Study: 20716817
Drug: tgAAC09 vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: tgAAC09 vaccine
Study: 17929487
Drug: Continuous epidural
Normalized name: ACCU-BLOC PERIFIX CONTINUOUS EPIDURAL ANESTHESIA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous epidural infusion of a local anesthetic
Study: 15546807
Drug: Lozenge containing
Normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lozenge containing lavender oil, extracts from hops, lemon balm and oat
Study: 15546807
Drug: Placebo lozenge
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo lozenge without active ingredients
Study: 10468903
Drug: MK-677 (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: MK-677 (25 mg/day; n = 12)
Study: 7817022
Drug: Intravitreal amikacin
Normalized name: Amikacin
DrugBank: Amikacin (DB00479)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravitreal amikacin and vancomycin, subconjunctival and topical antimicrobials and corticosteroids, systemic corticosteroids, immediate vitrectomy
Study: 7817022
Drug: Intravitreal amikacin
Normalized name: Amikacin
DrugBank: Amikacin (DB00479)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravitreal amikacin and vancomycin, subconjunctival and topical antimicrobials and corticosteroids, systemic corticosteroids, vitreous tap and treatment with or without intravenous antibiotics
Study: 3178249
Drug: 5% topical
Normalized name: BP 5% Topical Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5% topical bufexamac
Study: 22120857
Drug: Enalapril or
Normalized name: enalapril Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril or Amlodipine without Atorvastatin
Study: 15254494
Drug: Topical autologous
Normalized name: Autologous cultured fibroblasts
DrugBank: Azficel-T (DB11051)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical autologous serum application (20% diluted with physiological saline, applied four times a day for up to 12 weeks)
Study: 15254494
Drug: Topical antibiotic
Normalized name: Tetracycline and derivatives, topical antibiotics
DrugBank: Polymyxin B (DB00781)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical antibiotic and autologous serum
Study: 15254494
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (antibiotic alone)
Study: 15254494
Drug: Topical autologous
Normalized name: Autologous cultured fibroblasts
DrugBank: Azficel-T (DB11051)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical autologous serum application
Study: 10598691
Drug: Dorzolamide-timolol combination
Normalized name: dorzolamide / timolol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dorzolamide-timolol combination (2% dorzolamide and 0.5% timolol) given twice daily
Study: 9787367
Drug: Dorzolamide (2%)
DrugBank: Dorzolamide (DB00869)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dorzolamide (2%) three times daily and timolol (0.5%) twice daily
Study: 10598691
Drug: Dorzolamide-timolol combination
Normalized name: dorzolamide / timolol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dorzolamide-timolol combination (2% dorzolamide and 0.5% timolol) given twice daily during open-label extension
Study: 7616872
Drug: Estradiol implants
Normalized name: Oestradiol Implants
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estradiol implants 50 mg alone (E)
Study: 7616872
Drug: Estradiol 50
Normalized name: estradiol 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estradiol 50 mg plus testosterone 50 mg (E&T)
Study: 2239120
Drug: Methohexital 80
Normalized name: Methohexital
DrugBank: Methohexital (DB00474)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methohexital 80 mg/ml, 20 mg/kg rectally, 15 min before transportation
Study: 2239120
Drug: Pentobarbital 28
Normalized name: Pentobarbital
DrugBank: Pentobarbital (DB00312)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pentobarbital 28 mg/ml, 7 mg/kg rectally, 45 min before transportation
Study: 28681535
Drug: Treatment assignments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment assignments (aspirin/clopidogrel vs aspirin/placebo)
Study: 26220871
Drug: Telephone-based support
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telephone-based support (weekly for 12 weeks, 15-25 min/week)
Study: 23958393
Drug: Montelukast (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Montelukast (5 mg per day)
Study: 23958393
Drug: Fexofenadine HCl
Normalized name: fexofenadine HCl
DrugBank: Fexofenadine (DB00950)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fexofenadine HCl (60 mg per day)
Study: 18985740
Drug: Aprepitant triple
Normalized name: Aprepitant
DrugBank: Aprepitant (DB00673)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aprepitant triple therapy (125 mg p.o. on day 1, 80 mg on days 2 and 3, and 4 mg dexamethasone and ondansetron as specified)
Study: 18985740
Drug: Control regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control regimen (16 mg dexamethasone and ondansetron as specified)
Study: 18985740
Drug: Aprepitant triple
Normalized name: Aprepitant
DrugBank: Aprepitant (DB00673)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aprepitant triple therapy
Study: 17097819
Drug: Alcoholic drinks
Normalized name: Alcohol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alcoholic drinks (M=0.114 g% breath alcohol concentration [BrAC])
Study: 2907877
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg ofloxacin orally
Study: 2907877
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg ofloxacin orally
Study: 2907877
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg ofloxacin intravenously
Study: 29515226
Drug: Oral morphine
Normalized name: morphine Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral morphine (control)
Study: 18157705
Drug: Eslicarbazepine acetate
Normalized name: Eslicarbazepine Acetate
DrugBank: Eslicarbazepine (DB14575)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Eslicarbazepine acetate (800 mg once-daily for 8 days)
Study: 7752178
Drug: Enalapril (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril (20 or 40 mg/day)
Study: 2261364
Drug: Single course
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single course of cytotoxic therapy
Study: 2261364
Drug: Single course
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single course of cytotoxic chemotherapy
Study: 2261364
Drug: Prolonged adjuvant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prolonged adjuvant therapy (6 or 7 courses)
Study: 2261364
Drug: Prolonged cytotoxic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prolonged cytotoxic therapy
Study: 2261364
Drug: Prolonged therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prolonged therapy vs. one single course among node-positive patients
Study: 29202767
Drug: Glycopyrrolate 25
Normalized name: GLYCOPYRROLATE 25MCG/ML INHL 2 VIAL PKT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glycopyrrolate 25 μg BID
Study: 29202767
Drug: Glycopyrrolate 50
Normalized name: glycopyrrolate 500 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glycopyrrolate 50 μg BID
Study: 21282425
Drug: 600 mg
Normalized name: mesna 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg oral dose of efavirenz
Study: 16459222
Drug: Low glycemic
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low glycemic index diet with 30 g of soy protein and 4 g of phytosterols per day (LGID)
Study: 10919427
Drug: Low moisture‐conserving
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low moisture‐conserving performance (Group L)
Study: 8995494
Drug: Oral vinorelbine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral vinorelbine (Navelbine) at 80 mg/m2 per week after ingestion of a standard meal
Study: 8995494
Drug: Oral vinorelbine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral vinorelbine (Navelbine) at 80 mg/m2 per week in fasting state
Study: 8995494
Drug: Oral vinorelbine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral vinorelbine (Navelbine) at 80 mg/m2 per week in two divided doses
Study: 8995494
Drug: Chronic oral
Normalized name: Chromic Chloride
DrugBank: Chromic chloride (DB09129)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chronic oral administration of vinorelbine in two divided doses
Study: 1431363
Drug: CFPM 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: CFPM 2 g/day
Study: 1431363
Drug: CFPM 4
Approvals — FDA: no, EMA: no, PMDA: no
Description: CFPM 4 g/day
Study: 1431363
Drug: CAZ 2
Normalized name: Avycaz 2.5 GM Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: CAZ 2 g/day
Study: 4051271
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg intratracheal aerosolized etidocaine
Study: 4051271
Drug: 75 mg
Normalized name: talc 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75 mg intratracheal aerosolized etidocaine
Study: 21928099
Drug: GF Strong
Normalized name: Strongid
Approvals — FDA: no, EMA: no, PMDA: no
Description: GF Strong Water Protocol (GFSWP) - oral water intake, independent or supervised access, safe swallowing strategies
Study: 20039425
Drug: Tocilizumab (TCZ)
Normalized name: Tocilizumab
DrugBank: Tocilizumab (DB06273)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Tocilizumab (TCZ) 4 mg/kg or 8 mg/kg plus methotrexate (MTX)
Study: 17667889
Drug: Intravenous thrombolysis
Normalized name: thrombocytin
DrugBank: Serotonin (DB08839)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous thrombolysis (IV thrombolytic therapy)
Study: 17667889
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of IV and IA thrombolysis
Study: 11972576
Drug: Zolmitriptan orally
Normalized name: Zolmitriptan Orally Disintegrating Tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zolmitriptan orally disintegrating tablet 2.5 mg
Study: 10102964
Drug: FCB group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: FCB group (furazolidone 100 mg b.d. and clarithromycin 250 mg b.d. with tripotassium dicitrato bismuthate 240 mg b.d.)
Study: 10102964
Drug: FCL group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: FCL group (furazolidone 100 mg b.d. and clarithromycin 250 mg b.d. with lansoprazole 30 mg daily)
Study: 10102964
Drug: FCO group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: FCO group (clarithromycin 250 mg b.d. and omeprazole 20 mg daily with furazolidone 100 mg b.d.)
Study: 10102964
Drug: MCO group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: MCO group (clarithromycin 250 mg b.d. and omeprazole 20 mg daily with metronidazole 400 mg b.d.)
Study: 8547961
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of tumor necrosis factor (TNF) and actinomycin D
Study: 16208149
Drug: Hydrochlorothiazide (12.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrochlorothiazide (12.5 mg)
Study: 2180849
Drug: Enalapril and
Normalized name: enalapril and diuretics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril and Hydrochlorothiazide combination (32.5 mg)